- 4. A method according to Claim 3, wherein said dedimethylaminotetracycline is selected from the group consisting of 4-dedimethylaminotetracycline, 4-dedimethylamino-5-oxytetracycline, 4-dedimethylamino-7-chlorotetracycline, 4-hydroxy-4-dedimethylaminotetracycline, 5a,6-anhydro-4-hydroxy-4-dedimethylaminotetracycline, 6  $\propto$  -deoxy-5-hydroxy-4-dedimethylaminotetracycline, 6-demethyl-6-deoxy-4-dedimethylaminotetracycline, 4-dedimethylamino-12a-deoxytetracycline, 12 $\propto$  -deoxy-4-deoxy-4-dedimethylaminotetracycline, 12a, 4  $\propto$  -anhydro-4-dedimethylaminotetracycline, 7-dimethylamino-6-demethyl-6-deoxy-4-dedimethylaminotetracycline, 5-hydroxy-6-  $\propto$  -deoxy-4-dedimethylaminotetracycline, 4-dedimethylamino-12  $\propto$  -deoxyanhydrotetracycline and 4-dedimethylamino-11-hydroxy-12a-deoxytetracycline.
- 10. (Amended) A method according to Claim 1, wherein said tetracycline derivative is doxycycline.
- 11. A method according to Claim 1, wherein said tetracycline derivative is administered systemically.
- 12. A method according to Claim 11, wherein said tetracycline derivative is administered systemically by a controlled release delivery system.
- 13. A method according to Claim 1, wherein said tetracycline derivative is administered orally.
- 14. A method according to Claim 1, wherein said tetracycline derivative is administered topically.
- 18. A method of treating cataract formation in a mammal comprising administering to the mammal an effective amount of a tetracycline derivative.

Applicant(s): Ryan et al. Serial No.: 09/787,866 Filed: March 22, 2001 Page 3

- 19. A method according to Claim 18, wherein said tetracycline derivative is a non-antimicrobial tetracycline.
- 20. A method according to Claim 18, wherein said tetracycline derivative is a dedimethylaminotetracycline.
- 21. A method according to Claim 20, wherein said dedimethylaminotetracycline is selected from the group consisting of 4-dedimethylaminotetracycline, 4-dedimethylamino-5-oxytetracycline, 4-dedimethylamino-7-chlorotetracycline, 4-hydroxy-4-dedimethylaminotetracycline, 5a,6-anhydro-4-hydroxy-4-dedimethylaminotetracycline, 6 \infty deoxy-5-hydroxy-4-dedimethylaminotetracycline, 6-demethyl-6-deoxy-4-dedimethylaminotetracycline, 4-dedimethylamino-12a-deoxytetracycline, 12\infty -deoxy-4-dedimethylaminotetracycline, 12a, 4 \infty -anhydro-4-dedimethylaminotetracycline, 7-dimethylamino-6-demethyl-6-deoxy-4-dedimethylaminotetracycline, 5-hydroxy-6- \infty -deoxy-4-dedimethylaminotetracycline, 4-dedimethylamino-12 \infty -deoxyanhydrotetracycline and 4-dedimethylamino-11-hydroxy-12a-deoxytetracycline.

B

- 27. (Amended) A method according to Claim 18, wherein said tetracycline derivative is doxycycline.
- 28. A method according to Claim 18, wherein said tetracycline derivative is administered systemically.
- 29. A method according to Claim 28, wherein said tetracycline derivative is administered systemically by a controlled release delivery system.